Phase 2 Platform Randomized, Multicentre and Open Trial on the Efficacy and Safety of Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia (CLOPI-SNAP)

NCT07384702 Phase 2 NOT_YET_RECRUITING

The CLOPI-SNAP study is a randomized, multicenter, open-label clinical trial embedded within the SNAP (NCT 05137119) research platform. It constitutes a sub-study added to the core protocol for patients suffering Staphylococcus aureus bacteremia (SAB).

Details

Lead sponsor	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase	Phase 2
Status	NOT_YET_RECRUITING
Enrolment	230
Start date	2026-06
Completion	2030-06

Conditions

• Bacteremia Due to Staphylococcus Aureus

Interventions

• Clopidogrel
• No antiplatelet treatment

Primary outcomes

• Desirability of Outcome Ranking (DOOR) — At day 90 from day 0.
  Desirability of Outcome Ranking is an ordinal scale that classifies each patient's overall clinical outcome from 1 to 5, integrating survival, clinical response, and serious adverse events. DOOR 1 represents the most favorable outcome (alive with clinical cure or improvement and no serious adverse events); DOOR 2, clinical cure or improvement with serious adverse events; DOOR 3, alive with clinical failure and no serious adverse events; DOOR 4, clinical failure with serious adverse events; and DOOR 5, death, representing the least desirable outcome. Lower numerical values indicate more favorable overall clinical outcomes.

Countries

Spain